Staying ahead of JN.1: BNT162b2 mRNA vaccine for robust COVID-19 protection
IMPORTANCE
In order to apply for CME credits, Omnihealth Practice will collect your professional details and participation results for the corresponding College/ CME Programmes Administrator.
PLEASE ENSURE YOUR ACCOUNT DETAILS ARE CORRECT, including full name, and registration number. Omnihealth Practice is not responsible for any failure on application due to error details provided by participant. Should you have any questions, please contact [email protected]
To receive a certificate, you must achieve a passing score as designated by the corresponding college/ CME Programmes Administrator. You may view or print the certificate from RECORD, but you cannot alter it.
All the CME accredited programmes on Omnihealth Practice Education Portal are approved for healthcare professionals in Hong Kong SAR ONLY.
CME released:
29 November 2024
Valid for credit through:
28 January 2025
CME accredited by:
Hong Kong College of Community Medicine - 1.0
The Hong Kong College of Otorhinolaryngologists - 1.0
The Hong Kong College of Pathologists - 1.0
Hong Kong College of Paediatricians - 1.0
Hong Kong College of Physicians - 1.0
Medical Council of Hong Kong - 1.0 (Passive CME)
Endorsed by:
The Hong Kong Society for Infectious Diseases
About the programme
Despite the pandemic being declared over, Coronavirus Disease 2019 (COVID-19) continues to pose significant public health risks, particularly among the elderly. The JN.1 sublineages, which emerged in April 2024, have become dominant globally, exhibiting enhanced immune evasion and transmissibility. This highlights the urgent need for updated vaccines. The BNT162b2 messenger ribonucleic acid (mRNA) vaccine stands out as a leading candidate, demonstrating robust efficacy and safety across diverse populations, supported by clinical trials and real-world data. Importantly, it can be coadministered with the seasonal influenza vaccine without significant safety concerns, potentially facilitating higher vaccination rates. This comprehensive approach is crucial for addressing the evolving COVID-19 landscape and protecting public health.
Professor Hung, Fan-Ngai Ivan
Chair Professor,
Ru Chien and Helen Lieh Professorship in Health Sciences Pedagogy Head, Division of Infectious Diseases,
Associate Dean (Partnership & Engagement),
LKS Faculty of Medicine,
The University of Hong Kong
This is an independent editorial material, published and distributed through unrestricted educational support from Fosun Pharma for the purpose of continuing medical education only. The views expressed in this publication reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on editorial content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.